

Takeda Podcast

Improving CVD Risk in Patients With Type 2 Diabetes: A Multifactorial Approach
Session 2: Managing Dyslipidemia and the Prevention of Macrovascular Disease

References

Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. *Am J Med.* 2007;120(9 suppl 2):S12-S17.

Centers for Disease Control (CDC) and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Atlanta, Ga: US Department of Health and Human Services, CDC and Prevention; 2005.

Charbonnel B, Dormandy J, Erdmann E, et al. The prospective pioglitazone clinical trial in macrovascular events (PROactive). *Diabetes Care.* 2004;27:1647-1653.

Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. *JAMA.* 2003;289:2560-2572.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of high blood cholesterol. *JAMA.* 2001;285:2486-2497.

The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet.* 2005.366:1849-1861.

Fonseca VA. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. *Am J Med.* 2007;120(9 suppl 2):S18-S25.

Goldberg RB, Kendall DM, Deeg MA, et al, and the GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone in patients with type 2 diabetes and dyslipidemia. *Diabetes Care.* 2005;28:1547-1554.

Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. *N Engl J Med.* 2007;357:28-38.

Information for healthcare professional: rosiglitazone maleate (marketed as Avandia, Avandament, and Avandaryl). US Food and Drug Administration. Center for Drug Evaluation and Research.

<http://www.fda.gov/cder/drug/InfoSheets/HCP/rosiglitazone200707HCP.htm>. Accessed August 15, 2007.

Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med*. 2007;356:2457-2471.

Karalis DG. The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes. *Clin Cardiol*. Published September 10, 2007. Accessed September 14, 2007.

Rizzo M, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. *Exp Clin Endocrinol Diabetes*. 2007;115:477-482.

Rosen CJ. The rosiglitazone story—lessons from an FDA Advisory Committee Meeting. *New Engl J Med*. 2007;357:844-946.

Sobel BE. Optimizing cardiovascular outcomes in diabetes mellitus. *Am J Med*. 2007;120(9 suppl 2):S3-S11.